Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.
about
Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patientsNational Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group ReportThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseCorrelation and Agreement of Handheld Spirometry with Laboratory Spirometry in Allogeneic Hematopoietic Cell Transplant RecipientsEmerging uses of patient generated health data in clinical research.The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.FFS: an end(point) to our problems in chronic GVHD trials?National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.A "window of opportunity" for patients with late-onset pulmonary dysfunction after allogeneic hematopoietic cell transplantationBlood and marrow transplant clinical trials network state of the Science Symposium 2014Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group reporLate Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.A Critical Care and Transplantation-Based Approach to Acute Respiratory Failure after Hematopoietic Stem Cell Transplantation in Children.Confounding factors affecting the National Institutes of Health (NIH) chronic Graft-Versus-Host Disease Organ-Specific Score and global severity.How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantationEvolving concepts in prognostic scoring of chronic GvHD.Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation.Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.Lung Function Trajectory in Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplant.Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.Decreased pulmonary function in asymptomatic long-term survivors after allogeneic hematopoietic stem cell transplant.Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
P2860
Q26787230-B67AF4C5-A643-4E57-838D-7E2CCA6090C3Q26827651-97361F02-2615-48B1-BE0E-09B770025877Q28076264-3F897F4C-8CE2-4660-BF08-EE3EDDD6890FQ28391717-0BEE9410-EEEE-4AD0-B14B-148778431622Q30854718-6D1A03FD-4A96-4937-AC00-4BFB7977A6F4Q33625948-BFD3783E-5031-4D6F-8A6B-6A0AB2397A17Q34077766-4F1C9FCD-D8EC-46E3-84C6-082C8602BA73Q35085226-C110B54E-0ECF-4ABA-8C56-D8D11AC16500Q35445239-AB365272-9C43-4EA6-B0EB-AD9C7F92EFBFQ35591760-68F4FE0E-91DA-4FA7-BD5D-CB4CB020A00BQ36443116-D92D8983-3806-4AE2-A2FD-4E82E2CC195EQ36554724-2EBFD199-854D-43B0-A628-1C9E6C1E552DQ36675947-E4ACC8F4-8077-4487-B209-00A8EFB8E241Q36712018-40AF4D19-E0A5-444C-8E0F-158643DB5248Q37276584-74D5C7B5-CEB9-4386-9038-8C7CB89873BEQ37313795-C653BFC9-13AE-478F-B8B0-EC3738E335ABQ37609903-5E8B9499-52FC-4C2A-9D43-203604B472EDQ38739174-349F4E2F-C7EE-4B61-9585-035E17C8AAB5Q38937601-ED8AAF06-4F43-4FD2-9E69-F84AF1C171C8Q41387926-68065819-37A0-4EB4-BED5-1D8CBD8A3542Q42768766-3CE23D1F-4BB6-44F1-A28B-3FE385D6DC92Q47114304-7B910F8E-5D3C-4251-9934-10FADC593D29Q47930300-CEE85C3D-81E5-4AB2-A77E-4EDD8B78C820Q51624301-CCA5D8C1-1928-4F83-B2FE-AEBABF2C8E94
P2860
Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pulmonary symptoms measured by ...... nic graft-versus-host disease.
@en
Pulmonary symptoms measured by ...... nic graft-versus-host disease.
@nl
type
label
Pulmonary symptoms measured by ...... nic graft-versus-host disease.
@en
Pulmonary symptoms measured by ...... nic graft-versus-host disease.
@nl
prefLabel
Pulmonary symptoms measured by ...... nic graft-versus-host disease.
@en
Pulmonary symptoms measured by ...... nic graft-versus-host disease.
@nl
P2093
P2860
P50
P1476
Pulmonary symptoms measured by ...... onic graft-versus-host disease
@en
P2093
Corey Cutler
Daniel Weisdorf
David Jacobsohn
Georgia B Vogelsang
Jeanne Palmer
Joseph Pidala
Linus Santo Tomas
Madan Jagasia
Mukta Arora
Paul A Carpenter
P2860
P304
P356
10.1016/J.BBMT.2013.11.025
P577
2013-12-04T00:00:00Z